EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients

Eugenio De Corso iD, Davide Paolo Porru iD, Marco Corbò iD, Claudio Montuori iD, Gabriele De Maio iD, Rodolfo Francesco Mastrapasqua iD, Marco Panfili iD, Camilla Spanu iD, Giuseppe Alberto Di Bella iD, Giuseppe D'Agostino iD, Alberta Rizzuti iD, Giulio Cesare Passali iD und 1 weitere

Clinical Otolaryngology · 2024

DOI: 10.1111/coa.14172 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Otolaryngology, 2024. Verfasst von Eugenio De Corso und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Otorhinolaryngology and Head-Neck Surgery, "A. Gemelli" Hospital Foundation IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Management of severe chronic rhinosinusitis with nasal polyps (CRSwNP) has changed significantly in recent years, with different treatments now available including biologics and endoscopic sinus surgery (ESS), although there are still few comparative studies. We aimed to compare 1‐year outcomes of patients with severe CRSwNP treated with dupilumab or ESS plus intranasal corticosteroids (INCS).

Methods

In this retrospective, real‐life, observational, cohort study, we enrolled 101 patients with severe CRSwNP who were treated with INCS and either ESS ( n = 49) or dupilumab ( n = 52). The following outcomes were considered: nasal polyp score (NPS), Sino Nasal Outcome Test‐22 (SNOT‐22), visual analogue scale (VAS) for specific symptoms, Sniffin' Sticks identification test (SSIT), need for oral corticosteroids (OCS) and local eosinophilia detected by nasal cytology.

Results

ΔNPS was significantly higher in the surgery group up to 12 months when the difference with dupilumab group was no longer significant (ΔNPS: 4 vs. 4.1). ΔVAS rhinorrhoea, ΔVAS smell and ΔSNOT‐22 were significantly higher in the dupilumab group at 12 months ( p < .05). SSIT scores were significantly better in the dupilumab group starting from the first month of follow‐up ( p < .05). In the dupilumab group, only 6.1% of patients had detectable local eosinophilia compared to 57% in the surgery group alongside with a lower need for OCS (16.3% vs. 61%).

Conclusions

Both dupilumab and ESS were effective in improving outcomes in patients with severe CRSwNP over 12 months. Nevertheless, patients treated with dupilumab had greater improvement in terms of SNOT‐22, VAS rhinorrhoea, VAS smell and SSIT scores, with better control of local inflammation and less need for OCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSinusitisRhinitisNasal PolypsEndoscopyHumansMaleRetrospective StudiesFemaleChronic DiseaseMiddle AgedAdultTreatment OutcomeAdministration, IntranasalSeverity of Illness Index

Stichwörter der Autor:innen

ESSIL‐4biologicschronic rhinosinusitisdupilumabnasal polyps

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Unit of Otorhinolaryngology and Head-Neck Surgery, "A. Gemelli" Hospital Foundation IRCCS, Rome, Italy.
  • Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, Rome, Italy.
  • ENT Department, Rivoli Hospital, ASL TORINO 3, Torino, Italy.
  • Unit of Radiology, "A. Gemelli" University Hospital Foundation IRCCS, Rome, Italy.

ORCID-Profile: Eugenio De Corso, Davide Paolo Porru, Marco Corbò, Claudio Montuori, Gabriele De Maio, Rodolfo Francesco Mastrapasqua, Marco Panfili, Camilla Spanu, Giuseppe Alberto Di Bella, Giuseppe D'Agostino, Alberta Rizzuti, Giulio Cesare Passali, Jacopo Galli

Zitieren

APA

De Corso, E., Porru, D. P., Corbò, M., Montuori, C., De Maio, G., Mastrapasqua, R. F., Panfili, M., Spanu, C., Di Bella, G. A., D'Agostino, G., Rizzuti, A., Passali, G. C., & Galli, J. (2024). Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients. Clinical Otolaryngology. https://doi.org/10.1111/coa.14172

Vancouver

De Corso E, Porru DP, Corbò M, Montuori C, De Maio G, Mastrapasqua RF, et al. Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients. Clinical Otolaryngology. 2024. doi:10.1111/coa.14172

BibTeX
@article{DeCorso2024,
  author = {De Corso, Eugenio and Porru, Davide Paolo and Corbò, Marco and Montuori, Claudio and De Maio, Gabriele and Mastrapasqua, Rodolfo Francesco and Panfili, Marco and Spanu, Camilla and Di Bella, Giuseppe Alberto and D'Agostino, Giuseppe and Rizzuti, Alberta and Passali, Giulio Cesare and Galli, Jacopo},
  title = {Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients},
  journal = {Clinical Otolaryngology},
  year = {2024},
  doi = {10.1111/coa.14172}
}
Kostenlos starten →